Figure 1
From: Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
Annual hazard of disease recurrence in centrally confirmed HER2+ placebo patients in TEACH. HER2+, human epidermal growth factor receptor 2 positive; TEACH, Tykerb evaluation after chemotherapy.